Drug Trial Radar · NCT02508532
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Aug 2015
Primary completion
Mar 6, 2020
Study completion Jun 3, 2021
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).
Conditions
- Gastrointestinal Stromal Tumors (GIST)
- Other Relapsed or Refractory Solid Tumors
Interventions
AvapritinibDrug
avapritinib tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of AvapritinibTime frame: Cycle 1 (28 days) of treatment
- Parts 1 and 2: Number of Patients With Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: AEs were collected from the start of study drug until 30 days after the last dose, SAEs were collected from the date of the informed consent signature until 30 days after the last dose of study drug, up to 5 years
- Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Locations
19 sites in 10 countries. Site status is shown where the registry gives one.
Scottsdale Healthcare Hospitals DBA HonorHealth
Scottsdale, Arizona
Sarcoma Oncology Center
Santa Monica, California
Sylvester Comprehensive Cancer Center
Miami, Florida
Cancer Treatment Centers of America
Atlanta, Georgia
Dana Farber Cancer Institute
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center
New York, New York
Oregon Health and Science University
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Leuven Cancer Institute University Hospitals Leuven
Leuven, Belgium
Centre Leon Berard
Lyon, France
Institut Gustave Roussy
Paris, France
University of Duisburg-Essen
Essen, Germany
Fondazione IRCCS - Istituto Nazinale dei Tumori
Milan, Italy
Erasmus MC Cancer Institute
Rotterdam, Netherlands
Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie
Warsaw, Poland
Asan Medical Center
Seoul, South Korea
Vall d' Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Royal Marsden Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.